oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
A new model for in vitro testing of vitreous substitute candidates
Department of Ophthalmology, Lund University, Lund, Sweden .
Örebro universitet, Institutionen för läkarutbildning. Department of Ophthalmology, Örebro University Hospital, Örebro, Sweden.
Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, USA .
Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, USA .
Visa övriga samt affilieringar
2014 (Engelska)Ingår i: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 252, nr 10, s. 1581-1592Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To describe a new model for in vitro assessment of novel vitreous substitute candidates.

Methods: The biological impact of three vitreous substitute candidates was explored in a retinal explant culture model; a polyalkylimide hydrogel (Bio-Alcamid (R)), a two component hydrogel of 20 wt.% poly (ethylene glycol) in phosphate buffered saline (PEG) and a cross-linked sodium hyaluronic acid hydrogel (Healaflow (R)). The gels where applied to explanted adult rat retinas and then kept in culture for 2, 5 and 10 days. Gel-exposed explants were compared with explants incubated under standard tissue culture conditions. Cryosections of the specimens were stained with hematoxylin and eosin, immunohistochemical markers (GFAP, Vimentin, Neurofilament 160, PKC, Rhodopsin) and TUNEL.

Results: Explants kept under standard conditions as well as PEG-exposed explants displayed disruption of retinal layers with moderate pyknosis of all neurons. They also displayed moderate labeling of apoptotic cells. Bio-Alcamid (R)-exposed explants displayed severe thinning and disruption of retinal layers with massive cell death. Healaflow (R)-treated explants displayed normal retinal lamination with significantly better preservation of retinal neurons compared with control specimens, and almost no signs of apoptosis. Retinas exposed to Healaflow (R) and retinas kept under standard conditions showed variable labeling of GFAP with generally low expression and some areas of upregulation. PEG-exposed retinas showed increased GFAP labeling and Bio-Alcamid (R)-exposed retinas showed sparse labeling of GFAP.

Conclusions: Research into novel vitreous substitutes has important implications for both medical and surgical vitreoretinal disease. The in vitro model presented here provides a method of biocompatibility testing prior to more costly and cumbersome in vivo experiments. The explant culture system imposes reactions within the retina including disruption of layers, cell death and gliosis, and the progression of these reactions can be used for comparison of vitreous substitute candidates. Bio-Alcamid (R) had strong adverse effects on the retina which is consistent with results of prior in vivo trials. PEG gel elicits reactions similar to the control retinas whereas Healaflow (R) shows protection from culture-induced trauma indicating favorable biocompatibility.

Ort, förlag, år, upplaga, sidor
Hedidelberg, Germany: Springer, 2014. Vol. 252, nr 10, s. 1581-1592
Nyckelord [en]
Vitreous substitute, Immunohistochemistry, Retinal culture, Vitreoretinal surgery, Hyaluronic acid, Polyethylene oxide, Polyal kylimide
Nationell ämneskategori
Oftalmologi
Forskningsämne
Medicin
Identifikatorer
URN: urn:nbn:se:oru:diva-39809DOI: 10.1007/s00417-014-2714-3ISI: 000344631600009PubMedID: 25059475Scopus ID: 2-s2.0-84904522229OAI: oai:DiVA.org:oru-39809DiVA, id: diva2:772173
Forskningsfinansiär
Vetenskapsrådet
Anmärkning

Funding Agencies:

Faculty of Medicine, University of Lund

Princess Margareta's Foundation for Blind Children

Wallenberg Foundation

Sir General John Monash Scholarship

In Vivo Therapeutics Corporation

Tillgänglig från: 2014-12-16 Skapad: 2014-12-16 Senast uppdaterad: 2018-09-12Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Crafoord, Sven

Sök vidare i DiVA

Av författaren/redaktören
Crafoord, Sven
Av organisationen
Institutionen för läkarutbildning
I samma tidskrift
Graefe's Archives for Clinical and Experimental Ophthalmology
Oftalmologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 795 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf